Adding Mycophenolate to Standard Brain Cancer Treatment
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding a drug called mycophenolate mofetil (MMF) to standard treatment for newly diagnosed glioblastoma (a serious brain cancer) can help patients live longer and better. You'd receive the usual treatment—radiation and chemotherapy—plus the new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with glioblastoma (a type of brain cancer) and have not received any prior chemotherapy or radiation for it
- You are at least 18 years old and well enough to tolerate treatment (your doctor confirms this)
- Your blood counts and organ function (kidney, liver) are adequate to safely receive the treatments
- You have not had an allergic reaction to mycophenolate mofetil or temozolomide in the past
- You are not pregnant, not nursing, and able to use reliable birth control during and after treatment
- You do not have a serious active infection, immune system disorder, or history of organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This Phase 1/2 trial tests an “add-on” medicine (adjuvant therapy) for people newly diagnosed with glioblastoma (GBM) after standard chemoradiation. It aims to see how well the treatment works and how safe it is for patients following initial therapy.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
Hear when a new Advanced Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.